We have recommended the first under-the-tongue tablet immunotherapy shown to build long-term tolerance to allergens, which could help up to 27,000 people in England with moderate to severe birch tree pollen allergies.
NICE approves ribociclib combination therapy to help prevent cancer returning in early-stage disease.
The technologies could help healthcare professionals spot hidden spinal fractures in patients undergoing routine CT scans.
Some people with cystic fibrosis are set to benefit from a new once-daily triple therapy treatment, following NICE's recommendation of Alyftrek in final draft guidance published today.
Our annual report and accounts summarise our key achievements from April 2024 to March 2025.
NICE International has helped Egypt take a crucial step towards a fairer, more efficient healthcare system.
How NICE International is supporting evidence-based decision-making through the Regulatory Partnership for Growth Fund
We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing healthtech, while supporting a thriving life sciences industry in the UK.
